Pyronaridine/artesunate included in the list of WHO prequalified medicines | MMVPosted: May 22, 2012
Initially, Pyramax will be registered in areas of low malaria transmission where there is reported artemisinin resistance and diminished efficacy of other ACTs. Until further data after retreatment is obtained, Pyramax use will be restricted to a single course of treatment. Meantime, MMV and Shin Poong are conducting additional studies to investigate the safety of Pyramax after repeat-administration.
The Pyramax dossier has been submitted for regulatory approval to Myanmar and Vietnam, and is currently being processed. It is also being prepared for submission to Cambodia and Thailand.
Once approved in these countries, this ACT will serve as an important public health tool in WHO’s artemisinin resistance containment strategy. The prequalification of Pyramax is a key step towards the achievement of that goal.